SOURCES SOUGHT
A -- Needle-free mRNA Vaccine Delivery System
- Notice Date
- 6/2/2021 11:35:06 AM
- Notice Type
- Sources Sought
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- W6QK ACC-APG NATICK NATICK MA 01760-5011 USA
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY-21-S-0007
- Response Due
- 7/2/2021 1:00:00 PM
- Archive Date
- 07/17/2021
- Point of Contact
- Richard Totten, Phone: 3016192446
- E-Mail Address
-
richard.w.totten2.civ@mail.mil
(richard.w.totten2.civ@mail.mil)
- Description
- W911QY-21-S-0007 REQUEST FOR INFORMATION Needle-free mRNA Vaccine Delivery System Objective: This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited.� No solicitation document exists or is guaranteed to be issued as a result of this RFI. The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO CBRND) is seeking information on the capabilities and willingness of private entities (academic, non-profit and commercial) to design, test, manufacture, and serve as regulatory sponsor for an mRNA vaccine delivered by mechanisms other than traditional needle and syringe. Needle-free vaccine delivery technologies for consideration should ideally be easy to manufacture, transport, and store, and should be easy to administer/enable self-administration (example technologies include transdermal microneedle patches, oral formulations, aerosol formulations). A list of potential mRNA vaccine targets that the Government is interested in is provided in Appendix 1 below. The Government is requesting information on the following: Design, development, manufacturing using current Good Manufacturing Practices (cGMP), and lot release and stability testing of alternative non-traditional delivery techniques for mRNA vaccine delivery Formulation and stabilization of an mRNA construct for delivery via vaccine skin patch or alternative delivery techniques Utilization of alternative delivery techniques to elicit protective immune responses with a single dose and/or reduce cold-chain requirements Preclinical efficacy and safety testing of alternative needle-free vaccine delivery methods Regulatory sponsorship and execution of human clinical trials for safety, immunogenicity, and efficacy (if available) testing, and potential FDA Animal Rule development pathway Background:� JPEO CBRND is seeking information on capabilities for the development of a needle-free mRNA vaccine delivery system outlined in the objectives above. Executing this objective may include leveraging existing relationships between industry and academia, leveraging previously FDA-approved mRNA-based vaccine technologies, as well as leveraging any existing partnerships to satisfy FDA regulatory requirements necessary for future human safety and efficacy testing. Requirements: The purpose of this RFI is to request information on the ability to develop, manufacture, and test a needle-free method for the effective delivery of mRNA vaccines. JPEO CBRND would like to understand industry�s ability to: design and develop a needle-free method for effective immunization; formulate and/or stabilize mRNA vaccines for needle-free delivery; and test the vaccine and needle-free delivery method separately and in combination to demonstrate safe and effective vaccine delivery through preclinical studies and human clinical trials. �� Administration: The Government will retain comments and information received in response to this RFI. Proprietary information should be identified as Company Proprietary. Do not use Government security classification markings. All written responses must be received by COB on 2 Jul 2021. Responses should be sent by e-mail to: �usarmy.detrick.jpeo-cbd.mbx.mcs-rfi@mail.mil, with Subject Line of Responding Organization and RFI Title. Material that is advertisement only in nature is not desired. If a solicitation is subsequently released based on the responses to this RFI the first choice for an acquisition vehicle, if appropriate, will be the Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA).��� Respondents not already members of the consortium are encouraged to join at www.medcbrn.org.� Respondents may also inquire about the MCDC at mcdc@ati.org. Performance Objectives: When responding to this RFI, please provide responses to the objectives listed limited to 10 pages. Responses submitted should also include answers to all of the following prompts: Design, development, manufacturing, and testing of needle-free vaccine delivery system Describe �existing capability to design needle-free methods for vaccine delivery Design considerations and existing or planned testing of needle-free delivery method with/without mRNA vaccine Vaccine construct(s) tested with the needle-free design Describe existing or planned capability to manufacture mRNA vaccine delivery needle-free methods suitable for human use. Please address: Expected throughput and ability to scale up production Quality control and cGMP manufacturing mRNA vaccine formulation for needle-free delivery Describe existing capability to formulate and test mRNA vaccines for needle-free delivery. Please address: Product storage and transport conditions Product stability (time, temperature and any other requirements) Product stability testing considerations Describe experience in manufacturing and releasing sufficient quantities of cGMP material for Phase I-III human clinical trials Describe any current collaborations/partnerships with entities currently manufacturing clinical lots of mRNA vaccines for use in formulation studies Preclinical testing of vaccine needle-free delivery system safety and efficacy Describe experience in performing preclinical testing for U.S. regulatory applications Describe any current collaborations/partnerships with entities experienced in the design and conduct of preclinical studies for U.S. regulatory applications Regulatory sponsorship and execution of human clinical trials for safety and efficacy testing and/or FDA Animal Rule clinical trials where necessary Describe experience in serving as regulatory sponsor and obtaining FDA product approval(s) Appendix 1. Biological Threat List The Government interested in potential capabilities to address the following CBRN, pandemic influenza, and emerging infectious disease threats: Virus targets Filoviruses Pandemic influenza (H5 and H7 specifically) Alphaviruses Flaviviruses (Zika virus specifically) Arenaviruses Bunyaviruses Bacterial Plague Tularemia Melioidosis Glanders Q Fever Toxin threats Botulinum toxin Ricin Conotoxins Saxotoxins
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/31e2f6fdeb094b9eb57a2e6fd654dedf/view)
- Record
- SN06019698-F 20210604/210602230122 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |